The Company’s current clinical-stage programs are shown below.

Agennix Talactoferrin Development Pipeline

Agennix has Orphan Drug designation for NSCLC (from FDA) and RCC (from FDA and EMEA). This provides exclusivity for these lead indications, independent of patent protection, for seven years following U.S. marketing approval and ten years following European marketing approval.

Agennix has successfully scaled up its talactoferrin manufacturing process with 35,000 liter cGMP fermentation — a commercially economic production scale with an attractive COGS that is appropriate for commercial launch.